Polymyxin B

Identification

Summary

Polymyxin B is a polymyxin antibiotic used to treat a wide variety of infections in the body.

Brand Names

Casporyn HC, Cortisporin, Dioptrol, Diosporin, Diphen, Maxitrol, Neo-polycin, Neo-polycin HC, Neosporin Ointment, Neosporin Plus Maximum Strength, Neosporin Plus Maximum Strength Cream, Neosporin Solution, Polycin-B, Polysporin, Polytrim, Procomycin, Statrol, Triple Antibiotic

Generic Name

Polymyxin B

DrugBank Accession Number

DB00781

Background

Polymyxin B was discovered in the 1940s⁵. They are basic polypeptides of about eight amino acids and have cationic detergent action on cell membranes⁴. Polymyxin B is used for infections with gram-negative organisms, but may be neurotoxic and nephrotoxic^4,Label. All gram-positive bacteria, fungi, and the gram-negative cocci, are resistant⁴. It is appropriate for treatment of infections of the urinary tract, meninges, and blood stream, caused by susceptible strains of Pseudomonas aeruginosa^Label. Polymyxin B has a narrow therapeutic index and so its use is limited and unlikely to be used first line⁵.

Type

Small Molecule

Groups

Approved, Vet approved

Structure

Similar Structures

Weight: Average: 1203.499
Monoisotopic: 1202.74992728
Chemical Formula: C₅₆H₉₈N₁₆O₁₃

Synonyms

Polimixina B
Polymyxin B
Polymyxine B
Polymyxinum B

Poor quality drug data slowing you down?

Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.

Download eBook

Poor quality drug data slowing you down?

Download eBook

Pharmacology

Indication

Polymyxin B is indicated for the treatment of infections of the urinary tract, meninges, and blood stream, caused by susceptible strains of Pseudomonas aeruginosa^Label.

Reduce drug development failure rates

Build, train, & validate machine-learning models
with evidence-based and structured datasets.

See how

Build, train, & validate predictive machine-learning models with structured datasets.

See how

Associated Conditions

Indication Type	Indication	Combined Product Details	Approval Level	Patient Characteristics	Dose Form
Used in combination to treat	Acute otitis media	Combination Product in combination with: Neomycin (DB00994), Lidocaine (DB00281)	••• •••		••••••••• •••••••• • •••••
Treatment of	Bacteremia caused by enterobacter aerogenes		••••••••••••
Used in combination to treat	Bacterial conjunctivitis	Combination Product in combination with: Neomycin (DB00994), Prednisolone acetate (DB15566)	••••••••••••
Treatment of	Bacterial infections		••••••••••••
Treatment of	Bacterial meningitis		••••••••••••	••••••••••• ••••••••••

Contraindications & Blackbox Warnings

Prevent Adverse Drug Events Today

Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.

Learn more

Avoid life-threatening adverse drug events with our Clinical API

Learn more

Pharmacodynamics

Polymyxin B is an antibiotic that disrupts the outer cell membrane of Gram negative bacteria, binds and neutralizes lipopolysaccharide, and inhibits respiration of Gram-negative bacterial cells⁴. Polymyxin B can be given by a number of routes to treat susceptible Gram negative bacterial infections⁴. Absorption of the drug is poor (though not necessary for most of its activity) and the excreted drug is unchanged by metabolic processes^6,1. Polymyxin B is generally indicated for susceptible Gram negative infections of the urinary tract, meninges, and blood stream^Label.

Mechanism of action

The alpha and gamma diaminobutyric acid of a positively charged polymyxin B forms an electrostatic interaction with the phosphate groups of a negatively charged lipid A on the outer membrane of a Gram negative bacterium⁴. Calcium and Magnesium ions are displaced from phosphates of the membrane lipids, destabalising the lipopolysaccharide (LPS), increasing membrane permeability, causing cytoplasmic leaking, and killing the cell⁴.

Polymyxin B can also bind and neutralize LPS released during bacterial lysis, preventing reactions to endotoxin⁴.

A third activity of polymyxin B is the inhibition of type II NADH-quinone oxidoreductases in the bacterial inner membrane, which are essential for respiration⁴.

Polymyxin is active against common Gram negative bacteria but not Gram negative cocci, Gram positive bacteria, or anaerobic bacteria⁴.

Target	Actions	Organism
ABacterial outer membrane	incorporation into and destabilization	Bacteria

Absorption

Administration by the oral route does not lead to absorption⁴.

Volume of distribution

1 compartment models estimate the volume of distribution to be 34.3L to 47.2L¹. However, the general consensus is that the volume of distribution is yet to be determined⁸.

Protein binding

Polymyxin B is 79% to 92% bound to proteins⁸. Polymyxin B is likely 92 to 99% protein bound in circulation, though the exact proteins have not been identified³.

Metabolism

There is little data available for the metabolism of polymyxin B⁶. In one study, <1% of polymyxin B was eliminated through the kidneys and it had not been metabolised⁶. Polymyxin B has also been found in bile, not having undergone metabolic processes¹.

Route of elimination

Polymyxin B is proposed to be primarily eliminated through renal tubular reabsorption and non-renal pathways^1,8. Urine collection in humans and animals show <5% of polymyxin B eliminated from the kidneys¹. However, a Canadian product monograph states the drug is primarily eliminated through the kidneys and that 60% of polymyxin B is recovered in the urine⁸. This discrepancy can be explained by the 12 to 24 hour lag time between administration and significant elimination of polymyxin B⁸. Non-renal elimination is not well understood but all 4 components of polymyxin B have been detected in bile¹.

Half-life

In one study the half life was 9 to 11.5 hours¹. However, a Canadian monograph states the half life to be 6 hours, and 48-72 hours in patients with renal insufficiency⁸.

Clearance

1 compartment models estimate clearance to be 2.37L/h to 2.5L/h¹.

Adverse Effects

Improve decision support & research outcomes

With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!

See the data

Improve decision support & research outcomes with our structured adverse effects data.

See a data sample

Toxicity

Nephrotoxicity can occur in patients as polymyxin B is thought to accumulate in renal cells after renal tubular reabsorption¹. This accumulation can lead to apoptosis of renal cells and decrease in renal function². In recent studies, acute kidney injury (AKI) has been seen in 31.3% to 39.4% of patients receiving polymyxin B².

Overdose cases can cause neuromuscular block leading to apnea, muscular weakness, vertigo, transient facial parasthesia, slurred speed, vasomotor instability, visual disturbance, confusion, psychosis, and respiratory arrest⁸. Renal failure has also been seen through decreased urine output, and increased serum concentrations of blood urea nitrogen⁸.

Overdose of polymyxin B is treated by stopping the drug and beginning symptomatic treatment⁸. Intravenous administration of mannitol may enhance renal clearance, and hemodialysis may manage renal complications⁸.

Safety of polymyxin B has not been established in pregnancy, breast feeding, pediatrics, and geriatrics⁸. Polymyxin B should no be used in pregnancy unless the benefit outweighs the risk⁸. Nursing mothers should either stop nursing or stop polymyxin B treatment depending on the risks to both the mother and child⁸. Pediatric patients should be frequently monitored for renal function and no dosing information is available in children under 2 years of age⁸. Geriatric patients should have renal function assessed before and regularly during therapy⁸.

Pathways

Not Available

Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">

Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

Drug	Interaction
Integrate drug-drug interactions in your software
Aceclofenac	The risk or severity of adverse effects can be increased when Aceclofenac is combined with Polymyxin B.
Acemetacin	The risk or severity of adverse effects can be increased when Acemetacin is combined with Polymyxin B.
Acenocoumarol	The risk or severity of bleeding can be increased when Polymyxin B is combined with Acenocoumarol.
Acetophenazine	Acetophenazine may increase the neurotoxic activities of Polymyxin B.
Acetylsalicylic acid	The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Polymyxin B.

Food Interactions

No interactions found.

Products

Drug product information from 10+ global regions

Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.

Access now

Access drug product information from over 10 global regions.

Access now

Product Ingredients

Ingredient	UNII	CAS	InChI Key
Polymyxin B sulfate	19371312D4	1405-20-5	HFMDLUQUEXNBOP-OLYKAHIFSA-N

International/Other Brands

Aerosporin (GlaxoSmithKline) / Metamyxin (Pola Pharma) / Polomyxin B (Fuji Yakuhin) / Poly-Rx (X-Gen) / Polyfax (Intra) / Polyxx (Celon)

Brand Name Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End	Region	Image
Aerosporin Sterile Powder	Powder, for solution	500000 unit / vial	Intramuscular; Intrathecal; Intravenous; Respiratory (inhalation); Topical	Glaxo Wellcome	1952-12-31	1998-07-30
Polymyxin B for Injection USP	Powder, for solution	50 mg / vial	Intramuscular; Intrathecal; Intravenous; Ophthalmic	Sterimax Inc	2012-05-03	Not applicable

Generic Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Polymyxin B	Injection, solution	500000 1/1	Intramuscular; Intrathecal; Intravenous; Ophthalmic	Breckenridge Pharmaceutical, Inc.	2016-06-01	2019-03-31
Polymyxin B	Injection, powder, lyophilized, for solution	500000 [USP'U]/1	Intramuscular; Intrathecal; Intravenous; Ophthalmic	X-GEN Pharmaceuticals, Inc.	2014-01-15	2020-02-25
Polymyxin B	Injection, powder, lyophilized, for solution	500000 [USP'U]/1	Intramuscular; Intravenous	X-GEN Pharmaceuticals, Inc.	2014-04-25	2020-02-25
Polymyxin B	Injection, powder, for solution	500000 [iU]/1	Intramuscular; Intrathecal; Intravenous; Ophthalmic	Bedford Pharmaceuticals	1998-06-01	2014-03-31
Polymyxin B	Injection, powder, for solution	500000 [USP'U]/1	Intramuscular; Intrathecal; Intravenous; Ophthalmic	Xellia Pharmaceuticals USA LLC	2018-10-01	Not applicable

Mixture Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End
0.9g Triple Antibiotic	Polymyxin B sulfate (5000 [USP'U]/1g) + Bacitracin zinc (400 [USP'U]/1g) + Neomycin sulfate (0.0035 g/1g)	Ointment	Topical	Sled Distribution, LLC	2022-03-24	Not applicable
10 Person ANSI	Polymyxin B sulfate (5000 [iU]/1g) + Acetaminophen (325 mg/1) + Acetylsalicylic acid (325 mg/1) + Bacitracin zinc (400 [iU]/1g) + Benzalkonium chloride (0.13 g/100g) + Benzalkonium chloride (0.40 mL/100mL) + Benzocaine (6 mL/100mL) + Ethanol (60 mL/100mL) + Ibuprofen (200 mg/1) + Lidocaine (0.5 1/100g) + Neomycin sulfate (5 mg/1g) + Water (98.6 mL/100mL)	Kit	Ophthalmic; Oral; Topical	Genuine First Aid	2010-04-24	Not applicable
25 Person ANSI	Polymyxin B sulfate (5000 [iU]/1g) + Acetaminophen (325 mg/1) + Acetylsalicylic acid (325 mg/1) + Bacitracin zinc (400 [iU]/1g) + Benzalkonium chloride (0.13 g/100g) + Benzalkonium chloride (0.40 mL/100mL) + Benzocaine (6 mL/100mL) + Ethanol (60 mL/100mL) + Ethanol (62 g/100g) + Ibuprofen (200 mg/1) + Isopropyl alcohol (70 mL/100mL) + Lidocaine (0.5 g/100g) + Neomycin sulfate (5 mg/1g) + Water (98.6 mL/100mL)	Kit	Ophthalmic; Oral; Topical	Genuine First Aid	2010-04-25	Not applicable
4032 First Aid Kit	Polymyxin B sulfate (5000 [iU]/1g) + Acetylsalicylic acid (325 mg/1) + Ammonia (0.045 g/0.3mL) + Bacitracin zinc (400 [iU]/1g) + Benzalkonium chloride (1.3 mg/1mL) + Lidocaine hydrochloride (24.64 mg/1mL) + Neomycin sulfate (3.5 mg/1g) + Water (98.6 mL/100mL)	Inhalant; Kit; Liquid; Ointment; Spray; Tablet	Ophthalmic; Oral; Respiratory (inhalation); Topical	Honeywell Safety Products USA, Inc	2018-10-18	Not applicable
4042 First Aid Kit	Polymyxin B sulfate (5000 [iU]/1g) + Bacitracin zinc (400 [iU]/1g) + Benzalkonium chloride (0.13 g/100g) + Lidocaine hydrochloride (0.5 g/100g) + Neomycin sulfate (3.5 mg/1g) + Povidone-iodine (10 mg/1mL)	Kit	Topical	Honeywell Safety Products USA, Inc	2018-11-21	2019-10-18

Unapproved/Other Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End
4032 First Aid Kit	Polymyxin B sulfate (5000 [iU]/1g) + Acetylsalicylic acid (325 mg/1) + Ammonia (0.045 g/0.3mL) + Bacitracin zinc (400 [iU]/1g) + Benzalkonium chloride (1.3 mg/1mL) + Lidocaine hydrochloride (24.64 mg/1mL) + Neomycin sulfate (3.5 mg/1g) + Water (98.6 mL/100mL)	Inhalant; Kit; Liquid; Ointment; Spray; Tablet	Ophthalmic; Oral; Respiratory (inhalation); Topical	Honeywell Safety Products USA, Inc	2018-10-18	Not applicable
4042 First Aid Kit	Polymyxin B sulfate (5000 [iU]/1g) + Bacitracin zinc (400 [iU]/1g) + Benzalkonium chloride (0.13 g/100g) + Lidocaine hydrochloride (0.5 g/100g) + Neomycin sulfate (3.5 mg/1g) + Povidone-iodine (10 mg/1mL)	Kit	Topical	Honeywell Safety Products USA, Inc	2018-11-21	2019-10-18
4050 First Aid Kit	Polymyxin B sulfate (5000 [iU]/1g) + Bacitracin zinc (400 [iU]/1g) + Benzalkonium chloride (0.13 g/100g) + Lidocaine hydrochloride (0.5 g/100g) + Neomycin sulfate (3.5 mg/1g) + Povidone-iodine (10 mg/1mL)	Kit	Topical	Honeywell Safety Products USA, Inc	2018-11-21	2019-10-18
4064 First Aid Kit	Polymyxin B sulfate (5000 [iU]/1g) + Bacitracin zinc (400 [iU]/1g) + Benzalkonium chloride (0.13 g/100g) + Lidocaine hydrochloride (0.5 g/100g) + Neomycin sulfate (3.5 mg/1g) + Povidone-iodine (10 mg/1mL)	Cream; Kit; Ointment; Swab	Topical	Honeywell Safety Products USA, Inc	2018-11-21	2019-10-18
4065 First Aid Kit	Polymyxin B sulfate (5000 [iU]/1g) + Bacitracin zinc (400 [iU]/1g) + Benzalkonium chloride (0.13 g/100g) + Lidocaine hydrochloride (0.5 g/100g) + Neomycin sulfate (3.5 mg/1g) + Povidone-iodine (10 mg/1mL)	Cream; Kit; Ointment; Swab	Topical	Honeywell Safety Products USA, Inc	2018-11-21	Not applicable

Chemical Identifiers

UNII: J2VZ07J96K
CAS number: 1404-26-8
InChI Key: WQVJHHACXVLGBL-BPJDFBQWSA-N
InChI: InChI=1S/C56H98N16O13/c1-7-32(4)13-11-12-16-44(75)63-36(17-23-57)51(80)72-46(34(6)74)56(85)68-39(20-26-60)48(77)67-41-22-28-62-55(84)45(33(5)73)71-52(81)40(21-27-61)65-47(76)37(18-24-58)66-53(82)42(29-31(2)3)69-54(83)43(30-35-14-9-8-10-15-35)70-49(78)38(19-25-59)64-50(41)79/h8-10,14-15,31-34,36-43,45-46,73-74H,7,11-13,16-30,57-61H2,1-6H3,(H,62,84)(H,63,75)(H,64,79)(H,65,76)(H,66,82)(H,67,77)(H,68,85)(H,69,83)(H,70,78)(H,71,81)(H,72,80)/t32?,33-,34-,36+,37+,38-,39+,40+,41+,42+,43-,45+,46+/m1/s1
IUPAC Name: N-[(1S)-3-amino-1-{[(1S,2R)-1-{[(1S)-3-amino-1-{[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptaazacyclotricosan-21-yl]carbamoyl}propyl]carbamoyl}-2-hydroxypropyl]carbamoyl}propyl]-6-methyloctanamide
SMILES: [H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O

References

General References

Avedissian SN, Liu J, Rhodes NJ, Lee A, Pais GM, Hauser AR, Scheetz MH: A Review of the Clinical Pharmacokinetics of Polymyxin B. Antibiotics (Basel). 2019 Mar 22;8(1). pii: antibiotics8010031. doi: 10.3390/antibiotics8010031. [Article]
Nation RL, Rigatto MHP, Falci DR, Zavascki AP: Polymyxin Acute Kidney Injury: Dosing and Other Strategies to Reduce Toxicity. Antibiotics (Basel). 2019 Mar 14;8(1). pii: antibiotics8010024. doi: 10.3390/antibiotics8010024. [Article]
Abodakpi H, Gohlke J, Chang KT, Chow DS, Tam VH: Analytical and functional determination of polymyxin B protein binding in serum. Antimicrob Agents Chemother. 2015 Nov;59(11):7121-3. doi: 10.1128/AAC.01815-15. Epub 2015 Aug 31. [Article]
Poirel L, Jayol A, Nordmann P: Polymyxins: Antibacterial Activity, Susceptibility Testing, and Resistance Mechanisms Encoded by Plasmids or Chromosomes. Clin Microbiol Rev. 2017 Apr;30(2):557-596. doi: 10.1128/CMR.00064-16. [Article]
Velkov T, Roberts KD, Nation RL, Thompson PE, Li J: Pharmacology of polymyxins: new insights into an 'old' class of antibiotics. Future Microbiol. 2013 Jun;8(6):711-24. doi: 10.2217/fmb.13.39. [Article]
Zavascki AP, Goldani LZ, Cao G, Superti SV, Lutz L, Barth AL, Ramos F, Boniatti MM, Nation RL, Li J: Pharmacokinetics of intravenous polymyxin B in critically ill patients. Clin Infect Dis. 2008 Nov 15;47(10):1298-304. doi: 10.1086/592577. [Article]
SteriMax Inc: Polymyxin B for Injection USP Monograph [Link]
Product Monograph: Polymyxin B For Injection USP [File]

External Links

ChemSpider: 25045120
BindingDB: 50410807
RxNav: 8536
ChEMBL: CHEMBL1201283
Wikipedia: Polymyxin_B

FDA label

Download (219 KB)

MSDS

Download (127 KB)

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">

Phase	Status	Purpose	Conditions	Count
4	Completed	Prevention	Antibiotic Allergy / Antibiotic Side Effect / Eyelid Diseases / Eyelid; Wound / Postoperative Wound Infection / Skin Cancer Face / Surgical Incisions / Surgical Site Infections / Surgical Wound, Recent	1
4	Completed	Prevention	End Stage Renal Disease (ESRD)	1
4	Completed	Prevention	Urinary Tract Infection	1
4	Completed	Treatment	Actinic Keratosis (AK)	1
4	Completed	Treatment	Conjunctivitis	1

Pharmacoeconomics

Manufacturers

Not Available

Packagers

Not Available

Dosage Forms

Form	Route	Strength
Inhalant; kit; liquid; ointment; spray; tablet	Ophthalmic; Oral; Respiratory (inhalation); Topical
Cream; kit; liquid; ointment; swab	Topical
Gel; inhalant; kit; liquid; ointment	Ophthalmic; Respiratory (inhalation); Topical
Cream; kit; liquid; ointment; swab; tablet	Ophthalmic; Oral; Topical
Cream; kit; liquid; ointment; swab	Ophthalmic; Topical
Kit	Ophthalmic; Oral; Respiratory (inhalation); Topical
Kit	Ophthalmic; Respiratory (inhalation); Topical
Kit	Oral; Respiratory (inhalation); Topical
Kit; liquid; ointment; swab	Ophthalmic; Topical
Inhalant; kit; liquid; ointment; spray; swab; tablet	Ophthalmic; Oral; Respiratory (inhalation); Topical
Kit	Respiratory (inhalation); Topical
Gel; kit; liquid; ointment; swab	Ophthalmic; Topical
Inhalant; kit; liquid; ointment; spray; swab	Ophthalmic; Respiratory (inhalation); Topical
Kit; liquid; ointment; spray; swab	Ophthalmic; Topical
Cream; kit; liquid; ointment; spray; tablet	Ophthalmic; Oral; Topical
Cream; kit; liquid; ointment; swab; tablet	Oral; Topical
Cream; kit; liquid; ointment	Topical
Gel; kit; ointment; swab	Topical
Cream; kit; ointment; swab	Topical
Gel; kit; liquid; ointment	Ophthalmic; Topical
Kit; liquid; ointment; swab; tablet	Ophthalmic; Oral; Topical
Gel; kit; liquid; ointment; solution; swab	Ophthalmic; Topical
Kit; liquid; ointment; swab	Topical
Gel; kit; liquid; ointment	Topical
Gel; kit; liquid; ointment; swab	Topical
Cream; gel; kit; liquid; ointment; swab	Ophthalmic; Topical
Kit; liquid; ointment; spray; tablet	Ophthalmic; Oral; Topical
Cream; gel; kit; liquid; ointment; spray; swab	Ophthalmic; Topical
Kit; liquid; ointment	Topical
Gel; kit; liquid; ointment; swab; tablet	Oral; Topical
Kit; liquid; ointment	Ophthalmic; Topical
Kit	Irrigation; Ophthalmic; Respiratory (inhalation); Topical
Cream; irrigant; kit; liquid; ointment; swab	Irrigation; Ophthalmic; Topical
Kit	Irrigation; Oral; Respiratory (inhalation); Topical
Kit	Irrigation; Ophthalmic; Oral; Respiratory (inhalation); Topical
Kit	Oral; Topical
Kit	Topical
Powder, for solution	Intramuscular; Intrathecal; Intravenous; Respiratory (inhalation); Topical	500000 unit / vial
Solution	Other
Solution / drops	Oral
Solution	Auricular (otic); Ophthalmic
Ointment
Ointment	Cutaneous
Ointment; swab	Topical
Kit	Electro-osmosis
Cloth; kit; ointment; swab	Topical
Solution	Cutaneous
Cream	Topical
Solution	Auricular (otic)
Suspension	Topical
Kit	Oral
Cream; kit; liquid; ointment; tablet; tablet, chewable; tablet, film coated	Oral; Topical
Kit	Ophthalmic; Topical
Liquid	Topical
Solution	Auricular (otic); Topical
Kit	Ophthalmic; Oral; Topical
Cream; kit; tablet, film coated	Oral; Topical
Cloth; cream; gel; kit; ointment; solution	Ophthalmic; Topical
Kit	Ophthalmic
Lozenge	Buccal
Stick	Topical
Suspension	Conjunctival; Ophthalmic	1 mg
Solution	Conjunctival; Ophthalmic
Solution	Intravenous	5 mg
Solution	Intraocular; Ophthalmic
Irrigant	Irrigation
Solution	Irrigation
Ointment	Ophthalmic
Suspension	Ophthalmic
Solution / drops	Ophthalmic
Solution / drops	Auricular (otic)
Suspension / drops	Auricular (otic)
Suspension / drops	Ophthalmic
Suspension / drops	Topical
Solution	Urethral
Kit; ointment	Topical
Ointment	Conjunctival; Ophthalmic
Gel	Topical
Liquid	Auricular (otic)
Suspension	Auricular (otic)
Injection, powder, lyophilized, for solution	Intramuscular; Intrathecal; Intravenous	500000 IU
Solution	Ophthalmic	1.3 mg
Injection, solution	Intramuscular; Intrathecal; Intravenous	500000 iu
Injection, solution	Intramuscular; Intrathecal; Intravenous
Injection, powder, lyophilized, for solution	Intramuscular; Intrathecal; Intravenous
Liquid	Auricular (otic); Ophthalmic
Solution	Auricular (otic)	0.1 g/100ml
Capsule	Vaginal
Capsule	Vaginal	35000 iu
Injection	Intramuscular; Intrathecal; Intravenous	500000 1/1
Injection, powder, for solution	Intramuscular; Intrathecal; Intravenous; Ophthalmic	500000 [iU]/1
Injection, powder, for solution	Intramuscular; Intrathecal; Intravenous; Ophthalmic	500000 [USP'U]/1
Injection, powder, lyophilized, for solution	Intramuscular; Intrathecal; Intravenous	500000 [USP'U]/1
Injection, powder, lyophilized, for solution	Intramuscular; Intrathecal; Intravenous; Ophthalmic	500000 [USP'U]/1
Injection, powder, lyophilized, for solution	Intramuscular; Intrathecal; Intravenous; Ophthalmic	500000 [iU]/1
Injection, powder, lyophilized, for solution	Intramuscular; Intravenous	500000 [USP'U]/1
Injection, solution	Intramuscular; Intrathecal; Intravenous; Ophthalmic	500000 1/1
Powder, for solution	Intramuscular; Intrathecal; Intravenous; Ophthalmic	50 mg / vial
Injection, solution	Intramuscular; Intrathecal; Intravenous	500000 i.u.
Powder	Topical
Solution / drops	Auricular (otic); Ophthalmic
Ointment	Ophthalmic; Topical
Injection, powder, lyophilized, for solution	Intramuscular; Intrathecal; Intravenous	50000000000 IU
Lozenge	Oral
Cloth; kit; ointment	Topical
Solution	Intravenous	89.600 mg
Powder	Intramuscular; Intrathecal; Intravenous	500000 IU
Ointment	Topical
Solution	Ophthalmic
Jelly; kit; ointment	Topical
Suspension	Conjunctival; Ophthalmic
Swab	Topical
Liquid	Ophthalmic

Prices

Not Available

Patents

Not Available

Properties

State

Solid

Experimental Properties

Property	Value	Source
melting point (°C)	>203	MSDS
water solubility	Soluble	MSDS
pKa	8.9	https://www.chemicalbook.com/ChemicalProductProperty_US_CB8666707.aspx

Predicted Properties

Property	Value	Source
Water Solubility	0.0744 mg/mL	ALOGPS
logP	-0.89	ALOGPS
logP	-7.2	Chemaxon
logS	-4.2	ALOGPS
pKa (Strongest Acidic)	11.57	Chemaxon
pKa (Strongest Basic)	10.23	Chemaxon
Physiological Charge	5	Chemaxon
Hydrogen Acceptor Count	18	Chemaxon
Hydrogen Donor Count	18	Chemaxon
Polar Surface Area	490.66 Å²	Chemaxon
Rotatable Bond Count	29	Chemaxon
Refractivity	313.22 m³·mol^-1	Chemaxon
Polarizability	127.4 Å³	Chemaxon
Number of Rings	2	Chemaxon
Bioavailability	0	Chemaxon
Rule of Five	No	Chemaxon
Ghose Filter	No	Chemaxon
Veber's Rule	No	Chemaxon
MDDR-like Rule	No	Chemaxon

Predicted ADMET Features

Not Available

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum	Spectrum Type	Splash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)	Predicted LC-MS/MS	splash10-0udi-3390000000-364cd3f5c051fd282948
Predicted MS/MS Spectrum - 10V, Negative (Annotated)	Predicted LC-MS/MS	splash10-0ue9-0590000000-d0de5c17c416192b5e85
Predicted MS/MS Spectrum - 20V, Positive (Annotated)	Predicted LC-MS/MS	splash10-00ri-7920000020-754c2b9c3b89f80133a6
Predicted MS/MS Spectrum - 20V, Negative (Annotated)	Predicted LC-MS/MS	splash10-0a4r-3934000016-60010377a089e5b17dc9
Predicted MS/MS Spectrum - 40V, Positive (Annotated)	Predicted LC-MS/MS	splash10-00di-9400100021-f6058a5805e8cf3cec90
Predicted MS/MS Spectrum - 40V, Negative (Annotated)	Predicted LC-MS/MS	splash10-054n-9640100170-187ee07831c4d7d57b5b

Chromatographic Properties

Collision Cross Sections (CCS)

Not Available

Targets

Build, predict & validate machine-learning models

Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.

Learn more

Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.

Learn more

1. Bacterial outer membrane

Kind

Group

Organism

Bacteria

Pharmacological action

Yes

Actions

Incorporation into and destabilization

References

Yuan Z, Tam VH: Polymyxin B: a new strategy for multidrug-resistant Gram-negative organisms. Expert Opin Investig Drugs. 2008 May;17(5):661-8. doi: 10.1517/13543784.17.5.661 . [Article]
Zavascki AP, Goldani LZ, Li J, Nation RL: Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review. J Antimicrob Chemother. 2007 Dec;60(6):1206-15. Epub 2007 Sep 17. [Article]

Transporters

Details1. Solute carrier family 15 member 2

Kind: Protein
Organism: Humans
Pharmacological action: Unknown
Curator comments: Mediates drug reabsorption in the kidney

General Function: Peptide:proton symporter activity
Specific Function: Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides.
Gene Name: SLC15A2
Uniprot ID: Q16348
Uniprot Name: Solute carrier family 15 member 2
Molecular Weight: 81782.77 Da

References

Lu X, Chan T, Xu C, Zhu L, Zhou QT, Roberts KD, Chan HK, Li J, Zhou F: Human oligopeptide transporter 2 (PEPT2) mediates cellular uptake of polymyxins. J Antimicrob Chemother. 2016 Feb;71(2):403-12. doi: 10.1093/jac/dkv340. Epub 2015 Oct 22. [Article]

Drug created at February 28, 2019 16:07 / Updated at February 20, 2024 23:54

Polymyxin B

Identification

Structure for Polymyxin B (DB00781)

Pharmacology

Interactions

Products

Categories

Chemical Identifiers

References

Clinical Trials

Pharmacoeconomics

Properties

Spectra

Collision Cross Sections (CCS)

Targets

References

Transporters

References